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AbstrAct
Chronic lymphocytic leukemia (CLL) is an adult disease characterized by in 
vivo accumulation of mature CD5/CD19/CD23 triple positive B cells and is currently 
incurable. CLL cells undergo spontaneous apoptosis in response to in vitro cell 
culture condition but the underlying mechanism is unclear. We hypothesize that 
the sensitivity of CLL cells to spontaneous apoptosis may be associated with the 
constitutive activities of transcription factors STAT3 and/or NF-κB. We now show that 
the sensitivity of fresh CLL cells to spontaneous apoptosis is highly variable among 
different patients during 48 hours’ cell culture and inversely correlated with in vivo 
constitutively activated STAT3 and NF-κB (p < 0.001). Both activated STAT3 and 
NF-κB maintain the levels of anti-apoptotic protein Mcl-1/Bcl-xL and autocrine IL-6 
production. CLL cells with higher susceptibility to in vitro spontaneous apoptosis show 
the greatest chemosensitivity (p < 0.001), which is reflected clinically as achieving 
a complete response (CR) (p < 0.001), longer lymphocyte doubling times (p < 0.01), 
time to first treatment (p < 0.01), and progression free survival (p < 0.05). Our 
data suggest that the sensitivity of CLL cells to in vitro spontaneous apoptosis is 
co-regulated by constitutively activated STAT3 and NF-κB and reflects the in vivo 
chemo-responsiveness and clinical outcomes.
IntroductIon
Chronic lymphocytic leukemia (CLL) is the most 
common form of adult leukemia in western countries, 
and is characterized by the progressive accumulation 
of phenotypically mature monoclonal CD5+ malignant 
B-lymphocytes in peripheral blood (PB), bone marrow 
(BM), and lymphoid organs [1, 2]. Although there are 
improvements in clinical outcomes with current chemo-
immunotherapy, CLL remains incurable. Understanding 
the mechanisms that contribute to the survival and 
chemoresistance of CLL cells could lead to new and more 
effective therapeutic strategies.
Despite their longevity in vivo, circulating CLL 
cells rapidly undergo spontaneous apoptosis in vitro [3-6], 
indicating that in vitro conditions lack essential survival 
factors which are present in vivo. Many factors have 
been reported to reduce in vitro spontaneous apoptosis: 
such as bone marrow stromal cells [7, 8], nurse-like cells 
[9, 10], T cells [11] and dendritic cells [12] via cell-cell 
contact or secreted cytokines. The intracellular aberrant 
expression of Bcl-2 family of proteins, such as Bcl-2 [13], 
Mcl-1 [8] or Bcl-xL [4, 14-16] are associated with poor 
chemo-responsiveness and clinical prognosis as well as a 
decreased in vitro survival. 
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Transcription factors STAT3 and NF-κB are 
aberrantly activated in many cancer cells. These tumor-
associated transcription factors co-regulate gene 
expression, resulting in significant upregulation of 
genes involved in tumor cell survival, proliferation, and 
immunosuppression [17, 18]. NF-κB family proteins 
include RelA (p65), RelB, c-Rel, p50 (NF-κB1), and 
p52 (NF-κB2) transcription factors [17, 19]. The most 
commonly detected NF-κB dimer is RelA/p50 that is 
responsible for the processed a strong transcriptional 
activation domain and RelA is responsible for most of 
NF-κB transcriptional activity [19]. The constitutive 
phosphorylation of STAT3 on tyrosine 705 residues 
(p-STAT3Y705) is found in a wide variety of human cancer 
cells [20, 21]. However, in fresh primary CLL cells, 
p-STAT3Y705 is not detectable, whereas phosphorylation 
of STAT3 on serine 727 residues (p-STAT3S727) is 
constitutively expressed in all CLL cases [22, 23]. 
The mechanisms underlying constitutive p-STAT3S727 
expression in CLL cells remain unclear. Studies have 
shown that IL-6 induces STAT3 phosphorylation on both 
Tyr705 and Ser727 [23, 24]. The nuclear p-STAT3S727 
binds to DNA and mediates gene transcription [23], 
while mitochondrial p-STAT3S727 regulates mitochondrial 
respiration [25, 26].
Both STAT3 and NF-κB regulate the production of 
many cytokines, including IL-6, IL-8, IL-17, IL-21 and 
IL-23, and expression of anti-apoptotic proteins [27-29]. 
Many types of cancer cells can secrete IL-6 because of the 
constitutively activated STAT3 and NF-κB [30]. Autocrine 
and paracrine of IL-6 in turn maintain STAT3 and NF-
κB activities through direct or indirect signal pathways 
[31-33]. Although the cross-talking between STAT3 and 
NF-κB can further promote cancer cell proliferation and 
survival [17, 18, 33], it is unknown whether co-regulation 
of STAT3 and NF-κB plays an important role in CLL cell 
survival and disease progression.
Here, we aimed to determine whether constitutive 
activation of both STAT3 and NF-κB co-regulates in 
vitro CLL cell survival and disease progress in patients 
with CLL. We report for the first time that the sensitivity 
of CLL cells to spontaneous apoptosis reflects chemo-
responsiveness and disease progression in patients with 
CLL.
results
differential sensitivities of cll cells to in vitro 
spontaneous apoptosis
CLL is a disease of in vivo accumulation and CLL 
cells undergo rapid spontaneous apoptosis in the cultured 
condition [3, 6, 34]. We aimed to determine whether 
the sensitivity to spontaneous apoptosis varies among 
different CLL cases. The spontaneous apoptosis was tested 
in vivo (0 hour) and in vitro under cultured condition on 
51 fresh CLL samples. The sensitivities of CLL cells to 
spontaneous apoptosis were variable in individual CLL 
cases (Figure 1A), - the average spontaneous apoptosis 
over 51 CLL cases was 31.8%±13.5 at 48 hours’ time point 
(Figure 1B). The sensitivity of CLL cells to spontaneous 
cell death is not significantly correlated with Binet stage, 
treatment status, IgHV mutation, cytogenetic analysis, and 
the positivity of CD38 and ZAP70 (Figure 1C). Treatment 
with pan caspase inhibitor Z-VAD.fmk significantly 
decreased percentages of CLL cells that underwent 
spontaneous apoptosis (Figure 1D). While the data suggest 
that the intercellular survival signals play important role 
for spontaneous apoptosis in CLL cell survival, there was 
marked variation between different cases, implying that 
the degree of in vitro spontaneous apoptosis may reflect 
the underlying biology of the disease, as well as loss of in 
vivo signals. 
cll cells produce Il-6 during in vitro culture
CLL cells are long-lived in the circulation with 
survival signals from the protective microenvironment 
[3, 4]. Previous studies demonstrated the prevention of 
CLL cells from apoptosis is associated with presence of 
cytokines, such as IL-2, IL-4 [34], IL-6 [35], IL-10 [36], 
VEGF [37] and/or TNFα [38]. The levels of cytokine 
production, including IL-2, IL-4, IL-6, IL-10, TNFα and 
VEGF were determined in the plasma of patients and 
the supernatants from the cell culture. The levels of all 
cytokines in the cultured medium were significantly lower 
than those in the plasma, with many being undetectable 
in most cases (Figure 2A-2F), with the only exception 
of IL-6, which was similar in the supernatant and in 
the plasma (Figure 2C). All these cytokines have been 
reported to regulate in vivo cell growth and survival [34-
36]. After in vitro treatment with IL-2, IL-4, IL-6, IL-
10, TNFα or VEGF individually for 48 hours, all those 
cytokines significantly reduced the extents of CLL cell’s 
to spontaneous apoptosis (Figure 2G). Our previous study 
found that engagement of CD160 greatly increased IL-6 
production but no other cytokine [4]. These data indicate 
that in vitro spontaneous apoptosis of CLL may be related 
to the loss of multiple microenvironmental signals, while 
autocrine IL-6 might play an important role for in vitro 
survival of CLL cells.
Autocrine Il-6 production is co-regulated by 
STAT3 and NF-κB activities in CLL cells
STAT3 and NF-κB co-regulate IL-6 production in 
different cell types [30]. The interactions between STAT3 
and NF-κB family of proteins were predicted by the 
STRING v10 database (http://string-db.org/) [39]. STAT3 
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is highly interactive (both physically and functionally) 
with both RelA and NF-κB1 but not NF-κB2 (Figure 
3A and 3B). About 123 genes are co-regulated by both 
NF-κB and STAT3 [32]. The promoter region of IL-6 
gene contains binding sites of STAT3, RelA and NF-κB1 
(http://www.sabiosciences.com/). To explore whether 
the autocrine IL-6 were mediated by STAT3 and NF-κB 
activation in CLL, we tested the function of constitutively 
activated STAT3 and NF-κB by inhibiting transcriptional 
activities of STAT3 and NF-κB. Fresh CLL cells were 
treated with STAT3 inhibitors Stattic or 5,15-DPP and 
NF-κB inhibitors CAPE or JSH-23, respectively. The 
Figure 1: In vitro spontaneous apoptosis of fresh cll cells. Freshly isolated CLL cells were incubated in complete culture 
medium for 48 hours. A. Apoptotic cell death was measured by flow cytometry at 0 hour (without incubation) and after in vitro incubation 
for 48 hours in 2 CLL cases. b. Apoptotic cell death in 51 cases was determined by flow cytometry (mean ± SD). c. The level of 
spontaneous apoptosis in different clinical prognostic biomarker groups: Binet stage at presentation (A vs B/C, n = 51), treated vs untreated 
(n = 51), CD38 (negative or positive; cut-off 20%, n = 47), cytogenetic (absence or presence of 11q and 17p deletions, n = 48), ZAP-70 
(negative or positive; cut-off 20%, n = 26) and IgHV mutated vs unmutated (n = 16) cases. d. CLL cells were incubated with or without 
20µM Z-VAD.fmk for 24, 48 and 72 hours, then spontaneous apoptosis was analyzed by flow cytometry (n = 6). ** p < 0.01, ***p < 0.001.
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inhibition on either STAT3 transcription activity (by 
Stattic and 5,15-DPP) [40, 41] or RelA (by CAPE or 
JSH-23) [42, 43] significantly decreased autocrine IL-6 
production (Figure3C). The concentrations of inhibitors 
used for down-regulation of STAT3 and NF-κB did not 
significantly affect the autocrine of IL-2, IL-4, IL-10, 
TNFα and VGEF production (Figure 3D). These results 
indicate that autocrine IL-6 production was mediated by 
Figure 2: In vivo and in vitro cytokine production by cll cells. 5×105/ml of fresh CLL cells (CD19+/CD5+ more than 95%) 
were cultured in RPMI-1640 complete medium for 24 hours. The conditioned medium and corresponding plasma samples were incubated 
with cytokine beads and the levels of cytokine production were measured by flow cytometry: A. IL-2, b. IL-4, c. IL-6, d. IL-10, e. TNF-α 
and F. VGEF concentrations (n = 16). G. CLL cells were incubated with 10ng/ml of IL-2, 10ng/ml of IL-4, 10ng/ml of IL-6, 10ng/ml of 
IL-10, 10ng/ml of TNF-α or 10ng/ml of VGEF for 48 hours. Decreased percentages of apoptotic cell death mediated by cytokines were 
assessed by flow cytometry and compared with the untreated controls (n = 5). * p < 0.05, ** p < 0.01, ***p < 0.001.
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both STAT3 and NF-κB activation in CLL cells.
stAt3 and relA prevent cll cell apoptosis via 
an increase in expression of Mcl-1 and bcl-xl
The anti-apoptotic proteins Mcl-1 and Bcl-xL are 
target genes for both STAT3 and NF-κB [30, 33, 44, 45]. 
Inhibition of either STAT3 by Stattic and 5,15-DDP or 
NF-κB by JSH-23 and CAPE showed similar inhibitory 
effect on the expression of Bcl-2 family proteins: i.e. 
decreased expression of Mcl-1 and Bcl-xL, but not Bcl-2 
or Bax (Figure 4A and 4B). Global NF-κB and STAT3 
activities were analyzed as the sum of p-RelA+p-STAT3 
(Supplementary Figure 1A right panel). The levels of 
anti-apoptotic and pro-apoptotic proteins were analyzed 
accordingly in the same case (Supplementary Figure 
1B). The CLL cases with greater p-STAT3+p-RelA 
expression also showed higher levels of Bcl-xL+Mcl-1 
(Supplementary Figure 1B right panel). The levels of 
Mcl-1 plus Bcl-xL expression were significantly correlated 
with p-STAT3+p-RelA (p < 0.01, Supplementary Figure 
1C). Although the inhibition of STAT3 and NF-κB did 
not alter Bcl-2 or Bax expression, the global impact of 
decreased Mcl-1 and Bcl-xL could directly result in an 
increased spontaneous apoptosis (Figure 4C). These 
Figure 3: Co-regulation of STAT3 and NF-κB on autocrine IL-6 production. A. and b. Prediction of the interaction between 
STAT3 and NF-κB by STRING v10 database. A. Interaction network of STAT3 and NF-κB. The interaction network is generated by manual 
input of multiple human transcriptional factors. The thickness of the connection line reflects the binding score of two proteins. b. Combined 
association scores, including physical and functional interaction. c. d. Fresh CLL cells were incubated with 10µM of Stattic, 10µM of 
5,15-DDP, 10µM of CAPE or 10µM of JSH-23 for 24 hours in complete PRMI-1640 medium respectively. c. Autocrine IL-6 production 
(n = 9); d. IL-2, IL-4, IL-10, TNFα or VEGF (n = 4) production in the conditioned medium was determined by human CBA Flex kit and 
analyzed by flow cytometry.
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results were confirmed by transient knockdown of STAT3 
or NF-κB, which led to decreased expression of Mcl-1 and 
Bcl-xL (Figure 4D), and increased spontaneous apoptosis 
(Figure 4E). Transient knockdown of Mcl-1 and Bcl-xL 
for 24 hours results in a dramatic increase in spontaneous 
apoptosis in CLL cells (Figure 4E). Overall, these results 
demonstrate key roles of autocrine IL-6, expression of 
Mcl-1 and Bcl-xL - which are under the direct control 
of STAT3 and NF-κB activation in protecting against 
spontaneous apoptosis in CLL.
the degrees of autocrine Il-6 and spontaneous 
apoptosis reflect the level of constitutive activities 
of STAT3 and NF-κB in CLL cells
In CLL, STAT3 is uniquely phosphorylated 
at serine-727 (p-STAT3S727) rather than at tyrosine 
705 (p-STAT3Y705) [23]. Differential expression of 
p-STAT3S727 and p-RelA was determined by Western 
Blotting (Figure 5A). The heat map demonstrates that 
Figure 4: regulation of stAt3 and relA on bcl-xl/Mcl-1 expression and spontaneous apoptosis. Fresh CLL cells were 
incubated with 10µM of Stattic, 10µM of 5,15-DDP, 10µM of CAPE or 10µM of JSH-23 for 24 hours respectively. (A and B) Expression 
of Bcl-xL, Mcl-1, Bcl-2, and Bax was determined by Western blotting. c. Spontaneous apoptotic cell death for 48 hours incubation was 
detected by flow cytometry (n = 5). d. Down-regulation of STAT3 and RelA by siRNA. Cells were transfected with STAT3-siRNA, RelA-
siRNA or control siRNA. Expression of Mcl-1, Bcl-xL, STAT3, and RelA were determined by Western blotting. e. Cells were transfected 
with STAT3-siRNA, RelA-siRNA, Mcl-1-siRNA, Bcl-xL-siRNA or control siRNA and spontaneous apoptosis was determined by flow 
cytometry after transfection for 24 hours(n = 5).
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the levels of p-STAT3/p-RelA and autocrine IL-6 showed 
positive association, while the sensitivity of these cells to 
spontaneous cell death displayed a negative association 
with those three variables (Figure 5B). The correlation 
among these four variables of 20 cases of fresh CLL 
samples was statistically analyzed by the Pearson’s 
correlation. The levels of p-STAT3, p-RelA and autocrine 
IL-6 were significantly correlated with each other (Figure 
Figure 5: correlation of constitutive activities of stAt3 and relA with in vitro Il-6 production and spontaneous 
apoptosis. A. Constitutive activities of STAT3 and RelA. Expression of p-STAT3 and p-RelA was determined on 9 fresh CLL samples 
by Western Blotting. b. The association of expression of p-STAT3/p-RelA with IL-6 production and spontaneous cell death from 10 CLL 
cases (CLL ID) was expressed by a heat map. The levels of p-STAT3 and p-RelA expression ranged from 15-140 arbitrary units (AU) 
(analyzed by densitometry using GelScan v 5.1 software); autocrine IL-6 ranged from 0-40pg/ml and cell death ranged from 0-50%. (C, D, 
E) Correlation between p-STAT3 and p-RelA c. the correlation of IL-6 production to p-RelA d. or p-STAT3 e. was analyzed in 20 CLL 
cases. Correlation between spontaneous cell death and p-STAT3 F. or p-RelA G. was analyzed in 14 CLL cases. H. Correlation between 
IL-6 production and spontaneous cell death was analyzed in 38 CLL cases. 
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5C-5E), but higher expression of p-STAT3 or p-RelA 
was negatively and significantly correlated with the 
sensitivity of these CLL samples to spontaneous apoptosis 
(Figure 5F and 5G). This suggests that the corollary in 
vitro autocrine IL-6 and spontaneous apoptosis could be 
surrogate markers for in vivo STAT3 and NF-κB activities 
in CLL cells. To further explore the role of autocrine IL-6 
in CLL cell survival, the IL-6 production and spontaneous 
apoptosis were determined in 38 CLL cases. The median 
production of IL-6 was 6.68 pg/ml (range, 0.2-32 pg/ml, 
Supplementary Figure 2A), and the median of spontaneous 
cell death was 31% (range, 11-64%, Supplementary Figure 
2B). In general, CLL cells with higher IL-6 production 
(more than median) significantly correlated with less 
sensitivity to spontaneous cell death (Figure 5H). These 
results indicate that autocrine IL-6 not only reflects the 
degree of STAT3 and NF-κB activation, but also in vitro 
CLL cell survival.
Figure 6: correlation between constitutively activated stAt3 and relA with chemosensitivity. 5×106/ml of fresh CLL cells 
were treated with 20µg/ml of chlorambucil, cell death was determined by flow cytometry after 24 hours. A. and b. Correlation between 
chlorambucil-induced cell death and constitutive p-STAT3 (n = 15) or p-RelA (n = 15) expression. c. Correlation between spontaneous 
apoptosis and chlorambucil-induced cell death was analyzed in 38 CLL cases. d. Schematic illustration of the mechanisms by which 
STAT3/RelA co-regulate Bcl-xL and Mcl-1 expression, IL-6 production, and the chemoresistance. 
Oncotarget32039www.impactjournals.com/oncotarget
Constitutive activities of STAT3 and NF-κB 
negatively correlate with in vitro chemosensitivity 
of cll cells
We next determined whether the constitutive 
activity of STAT3 and NF-κB plays an important role 
in the resistance of CLL cells to chemotherapy. CLL 
cells were treated with chlorambucil (CBL) [24, 46] or 
fludarabine (FLU) [24, 47] for 24 hours. CBL or FLU-
induced cell death were inversely correlated with both 
STAT3 and NF-κB activation (p < 0.001, Figure 6A, 
6B and Supplementary Figure 3A, 3B). Importantly, 
the sensitivities of CLL cells to chemotherapy and 
spontaneous cell death were positively and significantly 
correlated (Figure 6C). Our results propose (Figure 6D) 
that, both constitutively activated STAT3 and NF-κB in 
CLL cells increased production of autocrine IL-6 and 
Figure 7: spontaneous apoptosis and clinical prognosis. Differential sensitivities to spontaneous apoptosis were analyzed. A. 
lymphocyte doubling time (LDT) more than 12 months and less than 12 months CLL cases; b. CLL cells from patients achieving a 
complete remission (CR, p < 0.01, n = 10) or non-CR (i.e., a partial response, stable disease and progressive disease; n = 19, p < 0.001). 
c. The significant difference between the CLL cells that were sensitive (i.e., more than average, n = 11) and those were resistant (less than 
average, n = 18) to spontaneous cell death in the time to first treatment (TTFT). d. The significant difference between the CLL cells that 
were sensitive (i.e., more than average, n = 23) and those that were resistant (less than average, n = 28) to spontaneous cell death in the 
progression free survival (PFS).
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expression of Bcl-xL and Mcl-1. The CLL cells with 
higher p-STAT3 and p-RelA activities have better in vitro 
survival and higher chemoresistance. In turn, higher levels 
of IL-6 reflect greater constitutive activities of STAT3 and 
NF-κB. 
Spontaneous cell death reflects in vivo chemo-
responsiveness and clinical outcome
One of most intriguing features of CLL is its clinical 
heterogeneity with some patients progressing rapidly 
with early death but others exhibit a more stable non-
progressive disease lasting many years. Thus, it is more 
important than ever to develop sensitive stratification 
parameters to identify patients with poor prognosis 
[48]. Lymphocyte doubling time (LDT), calculated 
by determining the number of months the absolute 
lymphocyte counts to be doubled, is widely used as 
measure of disease aggressiveness [48]. We assessed the 
correlation of LDT with in vitro spontaneous apoptosis 
and in vivo chemosensitivity. Patients were divided into 
two groups based on LDT longer than 12 months versus 
less than 12 months (Figure 7A); and their response to 
treatment: achieving a complete response (CR) versus not 
achieving a CR (i.e., a partial response, stable disease and 
progressive disease) (Figure 7B). CLL cases with a longer 
LDT ( > 12 months) were more sensitive to spontaneous 
apoptosis (31%±14.8) versus the cases with a shorter 
LDT ( < 12 months; 15%±8.5, p < 0.01, Figure 7A) and 
spontaneous cell death in the CR group was significantly 
higher than those in non-CR group (Figure 7B, mean 
39%±13 versus 19.7%±6.3 p < 0.001).
To further explore the correlation between 
spontaneous apoptosis and clinical prognosis, we analyzed 
the time to first treatment (TTFT) after diagnosis in the 
sensitive (more than average) and the resistant groups 
(less than average) to spontaneous apoptosis. The median 
of TTFT in the sensitive group was 4 years versus 1 year 
in the resistant group, while those cases with cells showing 
greater spontaneous apoptosis had longer TTFT (p < 0.05, 
Figure 7C). Furthermore, the median progression free 
survival (PFS) was significantly longer in patients with 
greater in vitro spontaneous apoptosis versus those cells 
were more resistant to spontaneous apoptosis (6 vs 3 
years, p = 0.046, Figure 7D). These results indicate that 
the degrees of in vitro spontaneous apoptosis of CLL cells 
are not only associated with the in vivo speed of CLL 
cell accumulation and chemo-responsiveness but also 
associated with clinical progression of this disease.
dIscussIon
In this study, we demonstrate, for the first time, that 
the sensitivities of CLL cells to in vitro spontaneous and 
drug-induced apoptosis are associated with the constitutive 
activities of both STAT3 and NF-κB. Activation of 
these transcription factors up-regulates autocrine IL-6 
production, and expression of anti-apoptotic proteins Mcl-
1 and Bcl-xL, leading to resistance of CLL cells to in vitro 
spontaneous apoptosis and chemotherapy. Importantly, the 
resistance of CLL cells to spontaneous apoptosis reflects 
poor clinical outcome and disease progression.
CLL cells are long-lived and accumulate in vivo but 
undergo spontaneous cell death when they are cultured 
in vitro [3, 6, 49, 50], which is attributable to a loss of 
microenvironmental survival signals [34]. We found 
that in vitro spontaneous and drug-induced apoptosis 
of CLL cells is highly variable among different cases, 
suggesting that intrinsic cell mechanisms primarily dictate 
cellular fate in this setting. The sensitivity of CLL cells 
to spontaneous apoptosis has also been proposed to be 
associated with homotypic interaction between CLL cells 
[50], IgVH mutation status [6], or CD160 expression on 
CLL B-cells [4]. However, the underlying mechanisms 
and the association between spontaneous and drug-
induced apoptosis in CLL cells are still unclear. 
We aimed to study the relationship between the 
activity of STAT3/NF-κB and in vitro spontaneous 
apoptosis, and the underlying mechanisms. Transcriptional 
factors, STAT3 and NF-κB, play crucial roles in 
carcinogenesis, cancer cell proliferation and survival in 
many types of cancers [31, 33, 51, 52]. The activation 
and the interaction between STAT3 and NF-κB play 
a key role in controlling dialog between malignant 
cell and its microenvironment [44]. Previous studies 
have demonstrated different modes of STAT3 and NF-
κB interaction in the transcriptional control: p-STAT3 
interacts with p-RelA to recruit the p300 HAT complex 
leading to RelA acetylation that mediates STAT3/NF-κB 
dependent gene transcription [30, 44]. STAT3 interacts 
with p50/NF-κB and/or RelA together they induce 
gene transcription through binding to composite sites 
[44]. Using STRING database, it was predicated that 
STAT3 and NF-κB interact physically and functionally, 
suggesting they bind to the same or different promoters 
and activate gene expression. In CLL cells, we found that 
there is marked heterogeneity in constitutively activated 
STAT3 and RelA. The activation of STAT3 and RelA are 
significantly correlated with each other, which reflects 
their in vivo levels of activation at the time of phlebotomy. 
STAT3 and NF-κB (RelA) both control Bcl-xL and Mcl-1 
expression, and IL-6 production. Inhibition or knockdown 
either p-STAT3 or p-RelA led to decrease in Bcl-xL/
Mcl-1 expression and IL-6 production but an increase in 
spontaneous cell death. In view of this, the concentration 
of autocrine IL-6 reflects the levels of STAT3 and NF-κB 
activities. Therefore, a positive correlation between the 
resistance to spontaneous cell death and autocrine IL-6 
production is unsurprising. 
It is well known that Mcl-1 and Bcl-xL are critical 
mediators of malignant cell survival in CLL [4, 53, 54]. 
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Both Bcl-xL and Mcl-1 are anti-apoptotic proteins, 
elevated expression of these proteins have been shown 
to prolong the survival of CLL cells exposed to a variety 
of apoptosis-inducing stimuli [55]. Furthermore, higher 
expression levels of Bcl-xL and Mcl-1 in CLL cells 
correlate with both poorer disease prognosis, and in vivo 
or in vitro chemo-resistance [53, 56, 57]. Our experiments 
demonstrated that STAT3 and NF-κB co-regulate Bcl-xL 
and Mcl-1 expression. Inhibition of either constitutive 
activation of STAT3 or NF-κB results in reduced both 
Bcl-xL and Mcl-1 expression but not Bcl-2. This finding 
explains the mechanism by which STAT3 and NF-κB 
prevent CLL cells from in vitro spontaneous apoptosis via 
sustaining the levels of Bcl-xL and Mcl-1. Similarly, the 
chemo-sensitization regulated by STAT3 and NF-κB is 
also dependent on Bcl-xL and Mcl-1 expression.
CLL is an accumulation disease that caused by 
failed in vivo spontaneous apoptosis or aberrant survival 
signal. LDT reflects in vivo CLL cell accumulation or 
disease progression [58]. The patients with LDT longer 
than 12 month showed more sensitive to spontaneous 
cell death. In contrast, the patients with LDT less than 
12 month exhibited more resistance to spontaneous cell 
death. The clinical outcomes of CLL are significantly 
different in individual patients: some patients will live 
for decades and never require treatment, while others 
having aggressive disease require treatment at initial 
presentation [59]. The patients with sensitive CLL cells to 
spontaneous apoptosis had longer time to first treatment 
compare with the resistant individuals (median was 4 year 
versus 1 year). Therefore, the sensitivity of CLL cells to 
in vitro spontaneous apoptosis might predict the disease 
progression for patients with CLL.
The notion that both STAT3 and NF-κB support 
cell survival not only has been proved by spontaneous 
cell death but also testified by in vitro chemotherapy-
induced cell death. CLL cells with higher activities of 
STAT3 or NF-κB manifested more resistant to drug-
induced apoptosis; moreover the chemo-sensitivity was 
positively correlated with their sensitivity to spontaneous 
apoptosis. To evaluate in vivo response to chemotherapy 
in CLL cells, we found that most of CLL patients with 
complete response to the treatment are more sensitive to 
spontaneous apoptosis compared with the non-CR cells. In 
addition, the patients being more sensitive to spontaneous 
apoptosis have better progression free survival than the 
patients with resistance to spontaneous apoptosis group.
In summary, we demonstrated that constitutive 
activation of STAT3 and NF-κB plays important roles for 
in vivo and in vitro survival in CLL cells. The sensitivity of 
CLL cells to in vitro spontaneous apoptosis and autocrine 
IL-6 production reflects the status of constitutive activities 
of STAT3/NF-κB, chemo-responsiveness and clinical 
outcome of patients with CLL. We therefore propose that 
the sensitivity to spontaneous apoptosis could be used as 
a surrogate marker to predict chemo-responsiveness for 
CLL patients. 
MAterIAls And MetHods
Patients, cell separation, cell culture and 
treatment
The protocol was approval by the National Research 
Ethics Service, East London, and the City Health Authority 
Local Research Ethics Committee for in vitro studies on 
blood samples from CLL patients. Fifty-one patients were 
enrolled in this study and the cases either had never been 
treated or had not received chemotherapy or steroids 
for over 6 months (Supplementary Table). Peripheral 
blood was obtained after written informed consent [4]. 
Peripheral blood mononuclear cells (PBMC) were isolated 
by density-gradient centrifugation over Ficoll-Paque (GE 
Healthcare). Freshly isolated CLL cells were suspended in 
complete RPMI-1640 medium containing 10% fetal calf 
serum, and 2 mM L-glutamine and cultured at 37°C in a 
humidified incubator with 5% CO2.
reagents
The reagents used were as followings: anti-
phosphorylated RelA, RelA and STAT3 were from 
Cell Signaling Technology; anti-Bcl-2 (100), anti-Bax 
(2D2), anti-Bcl-xL (s-18), and anti-Mcl-1 antibodies 
were purchased from Santa Cruz Biotechnology; anti-β-
actin antibody was from Sigma-Aldrich; anti-p-STAT3 
(phospho-STAT3-Ser-727, or p-STAT3S727) antibody and 
the Annexin V kit were purchased from BD Pharmingen; 
STAT3 inhibitors Stattic and 5-15 DPP were purchased 
from Sigma-Aldrich; RelA inhibitor caffeic acid 
phenethylester (CAPE) was from Alexis-Enzo Life 
Sciences and JSH-23 was from Calbiochem. 
Measurement of cytokines
Fresh CLL cells were isolated immediately after 
phlebotomy. The plasma was stored at -80°C. In all 
samples, the dual CD19+/CD5+ B-CLL cells were 
confirmed to represent more than 95% of the PBMCs. 
CLL B-cells in 5×106/ml were incubated for 24 hours and 
the supernatants were stored at -80°C until were assayed. 
Cytokine analysis was performed using the human CBA 
Flex kit (BD Biosciences) for simultaneous measurement 
of IL-2, IL-4, IL-6, IL-10, TNF-α and VEGF, according to 
the manufacturer’s instructions. Analysis was performed 
using a FACSCanto flow cytometer and FACSDiva 
software (BD Biosciences). The mean fluorescence 
intensity (MFI) was calculated using the CBA software 
(BD Biosciences) according to the standard curves and 
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cytokine concentrations (picograms per milliliter, pg/
ml). For IL-6 determination by ELISA, CLL cells were 
used immediately post-Ficoll (if CD5+/CD19+ cells 
were more than 95% of the PBMCs) or after magnetic-
bead purification of PBMC (CD19+ CLL cells great 
than 95%), incubated for 24 hours (5×106/ml) and IL-6 
concentrations in the plasma or culture supernatants were 
measured according to the manufacturer’s instructions 
(R&D Systems).
Western blotting
Proteins were extracted with CelLyticTM M cell 
Lysis Reagent (Sigma) supplied with protease inhibitor 
and phosphatase inhibitor cocktails (Sigma). Protein 
concentration was determined by the Bradford method, 
using the Bio-Rad Bradford reagent. Proteins were 
mixed with NuPAGE LDS Sample Buffer (Invitrogen) 
and boiled for 5 min. Proteins were then subjected to 
4-20% NuPAGE gels (Invitrogen) and transferred onto 
PVDF membrane (Sigma) at 20 V for 1 hour by semi-dry 
transfer. PVDF membrane was blocked with 5% non-fat 
milk in TBST for 1 hour and then incubated with primary 
antibodies overnight at 4°C against the indicated targets. 
Bound antibodies were detected using appropriate HRP-
conjugated secondary antibodies (Santa Cruz), visualized 
by GeneSnap (SynGene, Cambridge, UK) after adding 
ECL plus (GE Healthcare Life Science) [60, 61]. 
transfection of sirnA
Human STAT3, RelA, Mcl-1, Bcl-xL and control 
siRNA (Santa Cruz) were used to knockdown gene 
expression. Fresh primary CLL cells (5 × 107/ml) were 
suspended in 100µl of Human B Cell Nucleofector (R) 
reagent (Lonza) and 2µg of siRNA was added into the 
mixture. Transfection was performed using NucleofectorTM 
II apparatus with the program U-015 (Lonza). Transfection 
efficiency and protein expression were determined after 
transfection for 18 hours by flow cytometry or Western 
Blotting [60]. The cell death was determined by flow 
cytometry after transfection with PMAX-GFP plasmid for 
24 hours. 
determination of in vitro apoptosis
Apoptosis was determined using the Annexin 
V-FITC kit [49] .Briefly, fresh CLL cells were incubated 
with complete RPMI-1640 medium or treated by indicated 
cytokines or reagents. The percentages of Annexin V-FITC 
and propidium iodide (PI) positive cells were measured by 
flow cytometry (FACSCanto I). Annexin V-FITC and PI 
double-positive cells were defined as dead cells.
statistical analysis
Results are shown as mean ± SD or SEM from at 
least 4 individual cases. For statistical comparison between 
groups, the two-tailed paired or unpaired t test was used. 
GelScan V5.1 software was used to quantify protein 
expression on Western blots. The Pearson’s Correlation 
method was used to analyze the difference between two 
variables Graphpad Prism software. All P-values less than 
0.05 were considered statistically significant. *, ** and 
*** indicate P-value < 0.05, 0.01, and 0.001, respectively 
[62].
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